Reference system for characterization of Bordetella pertussis pulsed-field gel electrophoresis profiles

Journal of Clinical Microbiology

Volumn 42, Issue 7, 2004, Pages 2890-2897

  Advani, Abdolreza ^a   Donnelly, Declan ^a   Hallander, Hans ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; PERTACTIN; UNCLASSIFIED DRUG; XBAI PROTEIN;

ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM EXAMINATION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM SUBCULTURE; BORDETELLA PERTUSSIS; BORDETELLA PERTUSSIS BPSR11; BORDETELLA PERTUSSIS FIM3; BORDETELLA PERTUSSIS PW; EPIDEMIOLOGY; FREEZE DRYING; GENE EXPRESSION PROFILING; HEALTH CARE FACILITY; INFORMATION PROCESSING; MATERIALS; NONHUMAN; PRIORITY JOURNAL; PROFILE BASED REFERENCE SYSTEM; PULSED FIELD GEL ELECTROPHORESIS; REFERENCE SUBSTANCE; SEROTYPE; STANDARD; SWEDEN; UNITED STATES;

BORDETELLA PERTUSSIS; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; REPRODUCIBILITY OF RESULTS; SEROTYPING;

BACTERIA (MICROORGANISMS); BORDETELLA; BORDETELLA PERTUSSIS; NEGIBACTERIA;

EID: 3142663222     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.7.2890-2897.2004     Document Type: Article

References (29)

1. Ad Hoc Group for the Study of Pertussis Vaccines. 1988. Placebo-controlled trial of two acellular vaccines in Sweden: protective efficacy and adverse events. Lancet i:955-960.
2. Andrews, R., A. Herceg, and C. Roberts. 1997. Pertussis notifications in Australia, 1991 to 1997. Commun. Dis. Intell. 21:145-148.
3. Beall, B., P. K. Cassiday, and G. N. Sanden. 1995. Analysis of Bordetella pertussis isolates from an epidemic by pulsed-field gel electrophoresis. J. Clin. Microbiol. 33:3083-3086.
4. Bisgard, K. M., C. D. C. Christie, S. F. Reising, G. N. Sanden, P. K. Cassiday, C. Gomersall, W. A. Wattigney, N. E. Roberts, and P. M. Strebel. 2001. Molecular epidemiology of B. pertussis by pulsed-field gel electrophoresis profile: Cincinnati, 1989-1996. J. Infect. Dis. 183:1360-1367.
5. Cassiday, P., G. Sanden, K. Heuvelman, F. Mooi, K. M. Bisgard, and T. Popovic. 2000. Polymorphism in B. pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J. Infect. Dis. 182:1402-1408.
6. de Melker, H. E., M. A. E. Conyn-van Spaendonck, H. C. Rümke, J. K. van Wijngaarden, F. R. Mooi, and J. F. P. Schellekens. 1997. Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg. Infect. Dis. 3:175-178.
7. , de Moissac, Y. R., S. L. Ronald, and M. S. Peppler. 1994. Use of pulsed-field gel electrophoresis for epidemiological study of Bordetella pertussis in a whooping cough outbreak. J. Clin. Microbiol. 32:398-401.
8. Garcia-Corbeira, P., R. Dal-Re, L. Aguilar, and J. Garcia-de-Lomas. 2000. Seroepidemiology of B. pertussis infections in the Spanish population: a cross-sectional study. Vaccine 21:2173-2176.
9. Guiso, N., C. H. Wirsing von König, C. Becker, and H. Hallander. 2001. Fimbrial typing of Bordetella pertussis isolates: agglutination with polyclonal and monoclonal antisera. J. Clin. Microbiol. 39:1684-1685.
10. Guris, D., P. M. Strebel, B. Bardenheier, M. Brennan, R. Tachdjian, E. Finch, M. Wharton, and J. R. Livengood. 1999. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin. Infect. Dis. 28:1230-1237.
11. Gustafsson, L., H. O. Hallander, P. Olin, E. Reizenstein, and J. Storsaeter. 1996. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:349-355.
12. Gzyl, A., E. Augustynowicz, I. van Loo, and J. Slusarczyk. 2001. Temporal nucleotide changes in pertactin and pertussis toxin genes in B. pertussis strains isolated from clinical cases in Poland. Vaccine 20:299-303.
13. Hahm, B. K., Y. Maldonado, E. Schreiber, A. K. Bhunia, and C. H. Nakatsu. 2003. Subtyping of foodborne and environmental isolates of Escherichia coli by multiplex-PCR, rep-PCR, PFGE, ribotyping and AFLP. J. Microbiol. Methods 53:387-399.
14. Hardwick, T. H., P. K. Cassiday, R. S. Weyant, K. M. Bisgard, and G. N. Sanden. 2002. Changes in predominance and diversity of genomic subtypes of B. pertussis isolated in the United States, 1935 to 1999. Emerg. Infect. Dis. 8:44-49.
15. Hardwick, T. H., B. Plikaytis, P. K. Cassiday, G. Cage, M. S. Peppler, D. Shea, D. Boxrud, and G. N. Sanden. 2002. Reproducibility of Bordetella pertussis genomic DNA fragments generated by XbaI restriction and resolved by pulsed-field gel electrophoresis. J. Clin. Microbiol. 40:811-816.
16. Juretzko, P., R. von Kries, M. Hermann, C. H. Wirsing von König, J. Weil, and G. Giani. 2002. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin. Infect. Dis. 35:162-167.
17. Khattak, M. N., and R. C. Matthews. 1993. A comparison of the DNA fragment patterns of the mouse-virulent challenge strains and clinical isolates of B. pertussis. J. Infect. 27:119-124.
18. Mooi, F. R., H. Hallander, C. H. Wirsing von König, B. Hoet, and N. Guiso. 2000. Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur. J. Clin. Microbiol. Infect. Dis. 19:174-181.
19. Mooi, F. R., H. van Oirschot, K. Heuvelman, H. G. J. van der Heide, W. Gaastra, and R. J. L. Willems. 1998. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect. Immun. 66:670-675.
20. Olin, P., L. Gustafsson, L. Barreto, L. Hessel, T. C. Mast, A. van Rie, H. Bogaerts, and J. Storsaeter. 2003. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 21:2015-2021.
21. Parkhill, J., et al. 2003. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat. Genet. 35:32-40.
22. Peppler, M. S., S. Kuny, A. Nevesinjac, C. Rogers, Y. R. de Moissac, K. Knowles, M. Lorange, G. de Serres, and J. Talbot. 2003. Strain variation among Bordetella pertussis isolates from Quebec and Alberta provinces of Canada from 1985 to 1994. J. Clin. Microbiol. 41:3344-3347.
23. Stibitz, S., and M.-S. Yang. 1999. Genomic plasticity in natural populations of Bordetella pertussis. J. Bacteriol. 181:5512-5515.
24. Syedabubakar, S. N., R. S. Matthews, N. W. Preston, D. Owen, and V. Hillier. 1995. Application of pulsed field gel electrophoresis to the 1993 epidemic of whooping cough in the UK. Epidemiol. Infect. 115:101-113.
25. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
26. Tiru, M., P. Askelöf, M. Granström, and H. Hallander. 1997. Bordetella pertussis serotype of clinical isolates in Sweden during 1970-1995 and influence of vaccine efficacy studies. Dev. Biol. Stand. 89:239-245.
27. van Loo, I. H. M., J. Kees, A. Heuvelman, J. King, and F. R. Mooi. 2002. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J. Clin. Microbiol. 40:1994-2001.
28. Von König, C. H. W., S. Halperin, M. Riffelmann, and N. Guiso. 2002. Pertussis of adults and infants. Lancet Infect. Dis. 2:544-750.
29. Weber, C., C. Boursaux-Eude, G. Coralie, V. Caro, and N. Guiso. 2001. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J. Clin. Microbiol. 39:4396-4403.